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ABSTRACT 
Background: Self-monitoring of blood glucose levels is commonly performed by patients with diabetes mellitus. However, 
there is debate surrounding the clinical utility and cost-effectiveness of this practice among patients with type 2 diabetes 
managed without insulin. We conducted a systematic review and meta-analysis to determine the effect of self-monitoring 
versus no self-monitoring, and the optimal frequency of self-monitoring, in this population.
Methods: MEDLINE, EMBASE, BIOSIS Previews, CINAHL and PsycINFO were searched for randomized controlled tri-
als (RCTs) and observational studies published in English from January 1990 to March 2009. Additional citations were 
obtained through searches of the Internet and conference proceedings, and from stakeholder feedback. Two reviewers in-
dependently selected studies, extracted data and performed an assessment of the methodologic quality of the studies. Key 
outcomes of interest were hemoglobin A1c (HbA1c) concentration, hypoglycemia, quality of life, long-term complications of 
diabetes and death. Where appropriate, we pooled data using random-effects meta-analysis. 
Results: We identified 1624 citations through the literature search and selected 25 articles for inclusion. We observed a sta-
tistically significant improvement in the HbA1c concentration across RCTs that compared self-monitoring of blood glucose 
levels with no self-monitoring among patients taking oral antidiabetes drug therapy (weighted mean difference   –0.25%, 
95% confidence interval –0.36% to –0.15%). Subgroup analysis indicated that results from RCTs that provided patients with 
education on how to interpret and apply self-monitoring test results were similar to those from RCTs that did not. On the 
basis of limited evidence, self-monitoring of blood glucose levels did not demonstrate consistent benefits in terms of quality 
of life, patient satisfaction, prevention of hypoglycemia or long-term complications of diabetes, or reduction of mortality. 
There was insufficient evidence pertaining to the optimal frequency of self-monitoring.
Interpretation: Self-monitoring of blood glucose levels was associated with a modest, statistically significant reduction in 
hemoglobin A1c concentrations, regardless of whether patients were provided with education on how to interpret and use the 
test results. Further studies are required to determine whether self-monitoring reduces the risk of long-term complications 
of diabetes and to identify patients most likely to benefit from self-monitoring.
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D
iabetes  mellitus  is  associated  with  serious 
long-term complications and premature death.1,2 
In  2004/05,  diabetes  was  diagnosed  in  about 
5.5% (1.8 million) of Canadians 20 years of age and older.3 
Type 2 diabetes accounts for about 90% of all cases of 
diabetes.4 Maintaining a hemoglobin A1c (HbA1c) concen-
tration of 7% or less is recommended for all patients with 
diabetes to reduce the risk of long-term complications.2
Self-monitoring of blood glucose levels may contrib-
ute to glycemic control by allowing for adjustments in 
diet, physical activity and pharmacotherapy in response 
to test results. Although the need for self-monitoring in 
patients taking insulin is well established,2 the utility of 
the practice in patients with type 2 diabetes managed 
without insulin is controversial.5–8 Nevertheless, use of 
self-monitoring is highly prevalent in this population. 
In a recent study, people covered by the Ontario Public 
Drug Program whose diabetes was managed without in-
sulin submitted claims for 1.3 blood glucose test strips 
per day on average in 2006. This resulted in a total an-
nual cost of $69 million, or 63% of the Ontario Public 
Drug Program’s total expenditures on test strips.9 Apart 
from the economic costs, self-monitoring of blood glu-
cose  may  be  associated  with  patient  discomfort  and 
inconvenience.  Hence,  evidence-based  information  is 
needed to guide optimal use of this technology in pa-
tients with type 2 diabetes who do not use insulin.
Existing  systematic  reviews  in  this  area  have  re-
ported marginal advantages of self-monitoring of blood 
glucose levels in terms of controlling HbA1c, but they 
have not usually assessed other outcomes of interest 
such as hypoglycemia, long-term complications of dia-
betes or quality of life.10–16 Furthermore, previous re-
views have not accounted for differences across trials 
in the degree to which participants were educated on 
how to interpret and act on test results of self-mon-
itoring. This is a key limitation, since people using test 
strips must be able to act appropriately in response to 
abnormal readings if self-monitoring is to be effective. 
We therefore conducted a systematic review and me-
ta-analysis to determine the effect of self-monitoring 
versus no self-monitoring, and the optimal frequency 
of  self-monitoring,  in  patients  with  type  2  diabetes 
managed without insulin. We also assessed the effect 
of patient education regarding self-interpretation and 
application of test results on HbA1c concentrations and 
other clinical outcomes. This research was conducted 
as part of a larger initiative aimed at optimizing the use 
of this health technology (www.cadth.ca/index.php/en/
compus/blood-glucose).
Methods
This  systematic  review  was  conducted  according  to  a 
protocol developed a priori.17 Here, we summarize key 
methodologic aspects of the review.
Literature search. MEDLINE, MEDLINE In-Process 
& Other Non-Indexed Citations, EMBASE, BIOSIS Pre-
views, CINAHL and PsycINFO were searched for studies 
published in English from January 1990 to March 2009. 
We restricted the search to studies published after 1990 
to increase the likelihood that study conditions and prac-
tices  for  diabetes  management  were  reflective  of  cur-
rent practices. We also conducted parallel searches for 
studies in the Cochrane Library and Centre for Reviews 
and Dissemination databases. The search strategy com-
prised both controlled vocabulary, such as Medical Sub-
ject Headings, and key words. The main search concepts 
were  “blood  glucose  test  strips”  and  “type  2  diabetes 
mellitus.”  We  obtained  additional  citations  through 
searching the Internet and conference proceedings and 
from stakeholder feedback. (See online Appendix A for 
the complete literature search.)
Eligibility  criteria.  We  included  English-language 
full-text articles and conference abstracts of randomized 
controlled trials (RCTs) and observational studies (i.e., 
cohort,  case–control  and  time  series)  that  compared 
self-monitoring of blood glucose levels with no self-mon-
itoring, or that compared different frequencies of self-
monitoring, in adults or children with type 2 diabetes 
managed without insulin. To ensure a valid assessment 
of the efficacy of self-monitoring in this patient popula-
tion over a clinically relevant timeframe, we excluded 
studies that did not report outcomes by type of diabetes 
or type of therapy, were of less than 4 weeks’ duration, 
or demonstrated substantial differences between treat-
ment  groups  in  terms  of  management  practices  other 
than self-monitoring of blood glucose levels. 
Outcomes.  Outcomes  of  interest  included  measures 
of glycemic control; hypoglycemia; body weight; body 
mass  index;  hyperosmolar,  hyperglycemic,  nonketotic 
coma; generic and diabetes-specific health-related qual-
ity  of  life;  patient  satisfaction  with  diabetes  care  and 
treatment; efficacy of patient self-management of dia-
betes; and long-term complications of diabetes. In this 
article, we present results for HbA1c concentration, hypo-
glycemia, health-related quality of life, patient satisfac-
tion and long-term complications of diabetes. Results for 
other outcomes are presented elsewhere.18Open Medicine 2010;4(2):e104
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Data extraction. Two reviewers (2 of BM, KC, 
CY, AL) independently extracted data from each 
included article using a form designed a priori.18 
The following information was extracted: data for 
all relevant outcomes; study characteristics (e.g., 
inclusion and exclusions criteria); characteristics 
of  participants  (e.g.,  age,  duration  of  diabetes); 
and sources of funding. Disagreements were re-
solved by consensus or a third reviewer. Authors 
of the included studies were contacted if data were 
missing.
Quality  assessment.  The  2  reviewers  also 
independently  assessed  each  included  study’s 
methodologic  quality  using  modified  Scottish 
Intercollegiate  Guidelines  Network-50  instru-
ments for RCTs and cohort studies.19 This in-
formation was used in a sensitivity analysis to 
test the effect of removing poor-quality studies. 
Disagreements in quality assessment were re-
solved by consensus or a third reviewer.
Data  analysis.  We  pooled  data  across  RCTs 
using  Review  Manager  version  5.0  (Cochrane 
Collaboration)  with  random-effects  meta- 
analysis.20,21  The  decision  to  use  the  random-
effects model was based on clinical heterogen-
eity  of  patient  characteristics  (e.g.,  baseline 
HbA1c concentration)  and  of  trial  design  (e.g., 
testing frequency). We conducted sensitivity an-
alyses to test the effect of removing studies of 
poor quality, and the effect of removing studies 
that presented pooled results for patients tak-
ing  oral  antidiabetes  drug  therapy  (e.g.,  met-
formin,  sulfonylureas)  and  for  patients  taking 
no  pharmacotherapy.  Subgroup  analyses  were 
conducted  based  on  the  provision  of  educa-
tion on how to interpret and act on test results, 
medication class, frequency of self-monitoring, 
duration of self-monitoring and patient charac-
teristics. We assessed heterogeneity using the I  2 
statistic22 and publication bias using Egger’s test. 
We did not pool data from observational stud-
ies  because  of  a  high  degree  of  methodologic 
heterogeneity.
Results
Study selection. Of the 1624 citations identi-
fied through the literature search, we reviewed 
324  as  full-text  articles.  Twenty-six  articles, 
representing  9  RCTs  and  13  observational 
studies, were selected for inclusion (Fig. 1).8,23–47 In 2 instances, data 
from the same clinical trial were presented in multiple full-text 
articles: Farmer and colleagues,31 Simon and colleagues,39 French 
and  colleagues23  and  Farmer  and  colleagues46  reported  results 
from the Diabetes Glycaemic Education and Monitoring (DiGEM) 
trial, whereas the study by Siebolds and colleagues38 was an exten-
sion of the trial initially reported by Schwedes and colleagues.25 
Data from one observational study44 were not extractable.
Because we sought to isolate the effect of self-monitoring of 
blood glucose levels from other strategies for managing diabetes in 
patients with type 2 diabetes who do not use insulin, we excluded 
Figure 1: Selection of randomized controlled trials and observational 
studies on the efficacy of self-monitoring of blood glucose levels in 
patients with type 2 diabetes mellitus managed without insulin.
Studies included in qualitative analysis 
n = 21
Full-text articles assessed for eligibility
n = 324
      
         Excluded  n = 299
•  Duplicate study  n = 22
•  Study design not of interest  n = 27
•  Not an RCT or observational study  n = 75
•  Intervention not of interest  n = 4
•  Outcomes not reported by type of diabetes  n = 8
•  Comparators not of interest  n = 66
•  Recommendations/guidelines  n = 2
•  Abstract date before 2004  n = 1
•  Language other than English  n = 32
•  Outcomes not of interest  n = 21
•  Population not of interest  n = 5
•  Article described study protocol  n = 6
•  Research question not of interest  n = 19
•  Outcomes not reported by type of therapy  n = 6
•  Data not extractable  n = 1
•  Type 2 diabetes managed with insulin  n = 4
Excluded  n = 1300
    Population, intervention, comparators, outcomes 
or study design not of interest
Records identifi  ed through database 
searching  n = 1617
Records after duplicates removed 
n = 1082
Records screened 
n = 1624
Additional records identifi  ed 
through other sources  n = 542a number of studies included in past systematic reviews 
of self-monitoring. Appendix B (online) presents the rea-
sons for excluding a selection of these studies.
Among the included RCTs, 2 compared one frequency 
of self-monitoring with another frequency;29,43 7 compared 
self-monitoring  with  no  self-monitoring.8,24,25,31,34,35,38,45 
The DiGEM trial had 3 study groups: self-monitoring in 
combination with education on how to interpret and act 
on results, self-monitoring with usual care, and no self-
monitoring.23,31,39,46  There  was  considerable  variability 
across trials in the extent to which participants used oral 
antidiabetes drug therapy. In 2 studies, all of the partici-
pants used such therapy,24,43 whereas in the remaining 
7  RCTs,  some  participants  used oral  antidiabetes drug 
therapy while others used no antidiabetes pharmacother-
apy.8,23,25,29,31,34,35,38,39,45,46  The  proportion  of  participants 
who used oral antidiabetes drug therapy in these studies, 
where reported, ranged from 9%35 to 98%.8 Only 1 RCT 
reported subgroup data on participants who did not use 
antidiabetes pharmacotherapy.31
Study characteristics and methodologic quality. 
Sample sizes ranged from 2834 to 689 patients24 in the 
included RCTs, and from 11536 to 12 78627 in the obser-
vational  studies.  Study  duration  ranged  from  6  to  12 
months for the RCTs, and from 3 months42 to 6.5 years33 
for  the  observational  studies.  The  per-protocol  fre-
quency of self-monitoring in the RCTs varied from 1 strip 
per week29,43 to 6 strips per day for 6 days per week,8 al-
though actual use was significantly lower in most cases.
Four RCTs31,35,43,45 were rated as being of good meth-
odologic quality, and four8,24,25,34 as poor quality (online 
Appendix C). One RCT29 was reported as an abstract and 
could not be assessed for quality. The reasons for as-
signing ratings of poor quality were inadequate descrip-
tions  of  procedures  for  randomization  and  allocation 
concealment, high dropout rates, and failure to conduct 
an intention-to-treat analysis. All included observation-
al studies were rated as being of poor quality except for   
2 time-series studies,26,40 which could not be assessed for 
quality (online Appendix D).
Meta-analysis of studies involving patients using 
oral antidiabetes drug therapy
Effect of self-monitoring on HbA1c concentration. 
Seven RCTs (n = 2270) reported the effect of self-monitor-
ing of blood glucose levels versus no self-monitoring on 
change in HbA1c concentration from baseline.8,24,25,31,34,35,45 
The meta-analysis yielded a statistically significant differ-
ence in HbA1c in favour of self-monitoring (weighted mean 
difference –0.25%, 95% confidence interval [CI] –0.36% 
to –0.15%) (Fig. 2A, Table 1). Results were similar when 
we restricted the analysis to good-quality studies,31,35,45 or 
to studies in which all participants used oral antidiabet-
ic drug therapy (Table 1).24,31,45 There was no evidence of 
publication bias (Egger’s regression test; p = 0.29).48
We conducted a subgroup analysis based on whether 
study participants were instructed on how to interpret 
and  apply  results  from  self-monitoring  (Fig.  2B).  The 
pooled differences in HbA1c concentration were similar 
regardless of whether trials implemented such an educa-
tional component (Table 1). In the DiGEM trial, the only 
RCT that directly compared the effect of self-monitor-
ing combined with an educational component and self-
monitoring  combined  with  usual  care,  no  statistically 
significant difference in HbA1c concentration was found 
between study groups (mean difference 0.03%, 95% CI 
–0.15% to 0.21%).31
We  conducted  additional  subgroup  analyses  to  de-
termine  whether  the  HbA1c  estimate  was  affected  by 
differences across studies in the frequency or duration 
of  self-monitoring,  baseline  HbA1c  concentration,  time 
since diabetes diagnosis and type of oral antidiabetes 
drug  therapy  used  (Table  1).  Results  were  similar  to 
those from the overall analysis across all subgroups, al-
though the pooled estimate across the 2 trials25,34 that 
used an average frequency of self-monitoring of more 
than twice daily was somewhat higher than the pooled 
estimate across trials testing lower frequencies (mean 
difference –0.47%, 95% CI –0.79% to –0.15%). We found 
no  statistically  significant  effect  of  self-monitoring  on 
HbA1c concentration in the only RCT that enrolled newly 
diagnosed  patients  (mean  difference  –0.40%,  95%  CI 
–0.96% to 0.16%).35 
The only RCT comparing one frequency of self-mon-
itoring with another that reported HbA1c found no sig-
nificant difference at 6 months between a frequency of 
once per week compared with 4 times per week.43
Results  from  the  observational  studies  were  mixed 
with  respect  to  the  effect  of  self-monitoring  of  blood   
glucose on HbA1c levels (Table 2).27,28,32,36,37,40–42 In gener-
al, mean HbA1c levels were lower in patients performing 
self-monitoring  than  in  those  not  performing  self- 
monitoring,  and  higher  daily  frequencies  of  self- 
monitoring were associated with incremental reductions 
in HbA1c concentration. However, effect sizes varied con-
siderably across studies.
Effect of self-monitoring on other outcomes. The 
pooled relative risk for overall hypoglycemia across 3 RCTs 
reporting this outcome24,31,45 (n = 1752) was significantly 
higher with self-monitoring than with no self-monitoring 
Open Medicine 2010;4(2):e105
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ever, the rate of overall hypoglycemia was significantly 
lower (RR 0.73, 95% CI 0.55 to 0.98).35,45 There were no 
statistically significant differences in severe or nocturnal 
hypoglycemia (Table 3). However, Barnett and colleagues 
reported a statistically significant reduction in the number 
of symptomatic hypoglycemic events reported by patients 
using a sulfonylurea drug who performed self-monitoring 
compared with those who did not perform self-monitor-
ing (RR 0.57, 95% CI 0.38 to 0.85).45
Five RCTs reported the effect of self-monitoring on 
health-related  quality  of  life  and  patient  satisfaction 
(Table  4).23,24,35,38,39  There  were  no  statistically  signifi-
cant  differences  between  self-monitoring  and  no  self-
monitoring in terms of patient scores on the Well-being 
Questionnaire,23,38 the Diabetes Treatment Satisfaction 
Questionnaire23,25 or the overall EuroQol-5D score. In 
the DiGEM trial, quality of life measured using the Euro-
Qol-5D was significantly lower in the study arm in which 
patients  used  self-monitoring  and  received  intensive 
Open Medicine 2010;4(2):e106
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Figure 2: Effect of self-monitoring of blood glucose levels versus no self-monitoring on hemoglobin A1c concentration 
(change from baseline) in adults with type 2 diabetes managed without insulin. (A) Overall pooled estimate of effect from 
7 randomized controlled trials. (B) Results of subgroup analysis based on whether patients were provided with education on 
how to interpret and apply self-monitoring test results.education than in the arm in which patients did not use 
self-monitoring (mean difference –0.072, 95% CI –0.127 
to –0.017); this effect was due primarily to increased lev-
els of anxiety and depression.39 However, results from 2 
studies reporting subscale scores from the Well-being 
Questionnaire were conflicting with respect to the effect 
of self-monitoring on depression.35,38
Two  observational  studies30,33  that  compared  the 
effect  of  self-monitoring  with  no  self-monitoring  re-
ported mixed results for mortality. A retrospective co-
hort  study  involving  patients  with  newly  diagnosed 
diabetes  reported  that  self-monitoring  was  associated 
with significantly decreased risks of all-cause mortal-
ity and non-fatal diabetes-related events at 6.5 years.33 
Conversely,  a  prospective  cohort  study  involving  pa-
tients with previously diagnosed diabetes reported no 
change in all-cause mortality at 10 years associated with 
self-monitoring.30
Meta-analysis of studies involving patients not 
using oral antidiabetes drug therapy
One RCT subgroup analysis31 and 2 observational stud-
ies27,32 compared self-monitoring with no self-monitoring 
in  patients  managed  without  antidiabetes  pharmaco-
therapy. In the subgroup of participants in the DiGEM 
trial  not  taking  antidiabetes  agents,  HbA1c  concentra-
tions  did  not  differ  significantly  between  those  using 
self-monitoring test strips and those not using them, re-
gardless of whether users received intensive education in 
combination with self-monitoring.31 In contrast, a large 
retrospective  cohort  study  reported  statistically  signi-
ficant differences in HbA1c favouring self-monitoring.27 
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Table 1: Eff  ect on hemoglobin A1c (HbA1c) concentrations reported in RCTs comparing self-monitoring of blood glucose 
levels with no self-monitoring, or various frequencies of self-monitoring, among adults with type 2 diabetes managed 
without insulin
Analysis No. of studies (sample size)
Weighted mean diff  erence 
(95% CI), % I  2 value, %
Self-monitoring versus no self-monitoring
Overall 7 RCTs8,24,25,31,34,35,45 (n = 2270) –0.25 (–0.36 to –0.15) 0
Sensitivity and subgroup analyses 
Good-quality RCTs only 3 RCTs31,35,45 (n = 1247) –0.21 (–0.34 to –0.08) 0
Studies in which all participants used oral antidiabetes 
drugs
3 RCTs24,31,45 (n = 1628) –0.24 (–0.36 to –0.11) 0
Education regarding application of test results
   Education 3 RCTs25,31,35 (n = 710) –0.28 (–0.47 to –0.08) 17.8
   No education 5 RCTs8,24,31,34,45 (n = 1712) –0.22 (–0.34 to –0.10) 0
Average frequency of self-monitoring*
   < 1 test per day 3 RCTs8,24,31 (n = 1230) –0.20 (–0.35 to –0.06) 0
   1–2 tests per day 2 RCT35,45 (n = 794) –0.26 (–0.44 to –0.07) 0
   > 2 tests per day 2 RCTs25,34 (n = 246) –0.47 (–0.79 to –0.15) 0
Duration of self-monitoring
   6 months  5 RCTs8,24,25,35,45 (n = 1794) –0.28 (–0.41 to –0.15) 0
   > 6 months 3 RCTs31,34,35 (n = 660) –0.19 (–0.36 to –0.01) 0
Relation of diabetes to use of self-monitoring
   Previously diagnosed 6 RCTs8,24,25,31,34,45 (n = 2086) –0.25 (–0.35 to –0.14) 0
   Newly diagnosed 1 RCT35 (n = 184) –0.40 (–0.96 to 0.16) NA
Glycemic control at baseline
   HbA1c < 8.0% 1 RCT31 (n = 453) –0.16 (–0.34 to 0.03) NA
   HbA1c ≥ 8.0% 6 RCTs8,24,25,34,35,45 (n = 1817) –0.30 (–0.43 to –0.17) 0
Type of oral antidiabetes drug
   Sulfonylurea 1 RCT45 (n = 610) –0.24 (–0.43 to –0.05) NA
   Various 2 RCTs24,31 (n = 1018) –0.24 (–0.40 to –0.07) 0
Frequency of self-monitoring
Once per week v. 4 times per week 1 RCT43 (n = 178) –0.08 (–0.41 to 0.25) NA
 CI = confi  dence interval, NA = not applicable, RCT = randomized controlled trial.
*Average daily use of blood glucose test strips is based on actual testing frequency, when reported. Otherwise, it was assumed that participants adhered to testing 
  frequencies outlined in the study protocol.A  second  retrospective  cohort  study  reported  a  0.35% 
reduction  in  HbA1c  (p  <  0.001)  for  every  additional 
test strip dispensed per day among new users of self- 
monitoring, but not among patients who had used self-
monitoring for at least 3.5 years.32
Interpretation
Our systematic review identified 7 RCTs that compared 
self-monitoring  of  blood  glucose  levels  with  no  self-
monitoring  in  patients  with  type  2  diabetes  managed 
without insulin. The meta-analysis indicated that self-
monitoring was associated with a statistically significant 
improvement  in  HbA1c  concentration  of  0.24%  among 
patients receiving oral antidiabetes drug therapy, a result 
that is consistent with findings from previous systematic 
reviews.10–14,16 However, the clinical relevance of this ef-
fect is questionable in light of published minimal clinic-
ally important differences in HbA1c.49,50 Among patients 
who were not using antidiabetes pharmacotherapy, the 
improvement in HbA1c was even smaller and statistically 
nonsignificant.
We  did  not  pool  data  from  the  observational  stud-
ies because of the presence of substantial methodologic 
variation. Compared with RCTs, results from observa-
tional studies are more likely to be affected by selection 
bias, because patients who perform more frequent self-
monitoring may also be more likely to engage in lifestyle 
and health care utilization behaviours that lead to better 
glycemic control. This may explain, at least in part, why 
some observational studies have reported larger HbA1c 
benefits than RCTs have.27,40  
We also examined whether self-monitoring of blood 
glucose levels was more effective when used in conjunc-
tion with patient education regarding the interpretation 
of results and appropriate responses.11,15,51 We found that 
results from studies that provided such education were 
similar to those from studies that did not. This is con-
sistent with the results of the DiGEM trial, which also 
reported  no  significant  difference  in  glycemic  control 
between  patients  instructed  in  self-interpretation  and 
those who were directed to have a health professional in-
terpret results from self-monitoring.31 However, the ap- the ap-
parent lack of benefit from patient education could also 
be related to study factors such as poor compliance with 
the study protocol, or the lack of a specific algorithm for 
patients and clinicians to use self-monitoring test results 
to make therapeutic decisions.
According  to  the  Diabetes  in  Canada  Evaluation 
Study, the average HbA1c concentration among patients 
with type 2 diabetes in Canada is 7.5%, and only 20% 
of patients have a concentration in excess of 8.5%.52 Of 
the 7 RCTs included in our meta-analysis, 6 enrolled pa-
tients with a mean baseline HbA1c concentration of 8.1% 
to 10.5%. Therefore, our results may be more applicable 
to patients with poorly controlled diabetes. The DiGEM 
study, the only RCT that included patients with a base-
line HbA1c of less than 8.0%, reported a statistically non-
significant benefit of self-monitoring.31
Improvements in quality of life among patients using 
self-monitoring are typically attributed to a greater level 
of self-efficacy and control.53,54 Pain, discomfort and in-
convenience associated with self-monitoring may reduce 
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Table 2:  Mean diff  erences in hemoglobin A1c (HbA1c) concentrations reported in retrospective cohort studies comparing 
self-monitoring of blood glucose levels with no self-monitoring, or various frequencies of self-monitoring, among adults 
with type 2 diabetes managed without insulin
Analysis No. of studies (sample size)
Mean diff  erence in HbA1c 
concentration (95% CI), %
Self-monitoring v. no self-monitoring
≥ 1 strip per day v. no self-monitoring 1 R. cohort27 (n = 8735) –0.68 (–0.77 to –0.59)
< 1 strip per day v. no self-monitoring 1 R. cohort27 (n = 10243) –0.21 (–0.30 to –0.12)
Prescription of 2–4 strips per week v. no prescription of strips 1 R. cohort36 (n = 115) –0.20 (–0.77 to 0.37)
Prescription of 0.56 strips per day v. no prescription of strips 1 R. cohort41 (n = 299) –0.13 (–0.28 to 0.02)
Self-monitoring v. no self-monitoring among patients with baseline HbA1c ≥ 10% 1 time-series40 (n = 133) –0.63 (–1.14 to –0.12)
Frequency of self-monitoring
Once per day v. less than once per day 1 R. cohort27 (n = 6594) –0.47 (–0.57 to –0.37)
Increase of 1 strip per day
Patients using oral antidiabetes drug therapy 1 R. cohort37 (n = 1795)   0.09 (p = 0.54)
Patients using sulfonylurea agent 1 R. cohort42 (n = 216)    0.02 (p > 0.50)
New users of test strips 1 R. cohort32 (n = 5546)  –0.42 (p < 0.001)
Prevalent users of test strips 1 R. cohort32 (n = 7409)  –0.16 (p < 0.001)
Increase of 10 test strips per week 1 R. cohort28 (n = 5862) –0.06 (p = 0.38)
CI = confi  dence interval, R. cohort = retrospective cohort.quality of life.53–58 In our analysis, we found no signifi-
cant  differences  between  self-monitoring  and  no  self-
monitoring in terms of overall health-related quality of 
life, patient satisfaction or patient well-being, although 
evidence  for  these  outcomes  was  sparse  and  analysis 
was complicated by the use of different scales. Analysis 
of subscales related to psychological well-being demon-
strated discrepant findings across studies with respect to 
the effect of self-monitoring on anxiety and depression. 
The available data on the effects of self-monitoring on 
quality of life and patient satisfaction are thus inconclu-
sive.  Further  studies  using  standardized  instruments 
are required to determine the benefits, if any, of self-
monitoring on these outcomes.
The  relative  risks  for  severe  and  nocturnal  hypo-
glycemia  were  not  significantly  affected  by  self- 
monitoring, but the risk of overall hypoglycemia was 
significantly higher with self-monitoring than with no 
self-monitoring. This was likely due to greater detec-
tion  of  asymptomatic  hypoglycemia.10,14,24,45  Interest-
ingly,  the  number  of  events  of  overall  hypoglycemia 
was significantly lower with self-monitoring. The rea-
son for this counterintuitive result is unclear, although 
it may be that increased detection of hypoglycemia with 
self-monitoring soon after initiation of self-monitoring 
(which results in a higher relative risk) ultimately pro-
duces  behavioural  changes  that  reduce  future  hypo-
glycemic  events  (resulting  in  a  lower  rate  ratio).  The 
finding by Barnett and colleagues that rates of symp-
tomatic hypoglycemia were lower among patients given 
a  sulfonylurea  agent  who  performed  self-monitoring 
than  among  those  who  received  the  pharmacother-
apy alone45 may indicate that self-monitoring prevents 
asymptomatic  hypoglycemia  from  progressing.  How-
ever, this is a highly subjective outcome that is likely 
prone  to  ascertainment  bias.  Further  studies  using 
more rigorous methods are therefore required to con-
firm this possible benefit of self-monitoring.
Data regarding long-term clinical outcomes were in-
frequently reported in observational studies, and no such 
data were reported in RCTs. Given the high likelihood 
of selection bias in observational studies, further RCTs 
of adequate size and duration are required to determine 
whether  self-monitoring  reduces  long-term  complica-
tions of diabetes in patients with type 2 diabetes who do 
not use insulin.
Strengths and limitations. In this review, we sys-
tematically evaluated the available evidence from RCTs 
and observational studies related to self-monitoring of 
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Table 3:  Eff  ect on overall, severe and nocturnal hypoglycemia reported in RCTs comparing self-monitoring of blood glucose levels 
with no self-monitoring, or various frequencies of self-monitoring, among adults with type 2 diabetes managed without insulin
Analysis No. of studies (sample size) Eff  ect estimate (95% CI) I  2 value, %
Self-monitoring v. no self-monitoring 
Overall hypoglycemia 3 RCTs24,31,45 (n = 1752) RR 1.99 (1.37 to 2.89) 33.8
2 RCTs35,45 (n = 794) Rate ratio 0.73 (0.55 to 0.98) 0
Severe hypoglycemia 3 RCTs25,31,45 (n = 1752) RR 0.17 (0.01 to 4.12) NA
Nocturnal hypoglycemia 1 RCT45 (n = 610) RR 0.41 (0.11 to 1.58) NA
Frequency of self-monitoring (once per week v. 4 times per week)
Overall hypoglycemia 1 RCT43 (n = 202) RR 0.28 (0.11 to 0.73) NA
Severe hypoglycemia 1 RCT43 (n = 202) No events NA
CI = confi  dence interval, NA = not applicable, RR = relative risk, RCT = randomized controlled trial.
Table 4: Mean differences in patient satisfaction with diabetes treatment, well-being and quality of life reported in RCTs comparing  
self-monitoring of blood glucose levels with no self-monitoring among adults with type 2 diabetes managed without insulin 
Analysis No. of studies (sample size) Weighted mean difference (95% CI), %
Treatment satisfaction (DTSQ) 2 RCTs23,24 (n = 562) –0.26 (–1.38 to 0.86)
Well-being (WBQ-12) 1 RCT23 (n = 339) –0.85 (–2.27 to 0.56)
Well-being (WBQ-22) 1 RCT38 (n = 223) 1.83 (–0.05 to 3.71)
Quality of life (EQ-5D)
Self-monitoring overall 1 RCT39 (n = 453) –0.06 (–0.13 to 0.02)
Self-monitoring with education 1 RCT39 (n = 302) –0.029 (–0.084 to 0.025)
Self-monitoring without education 1 RCT39 (n = 301) –0.072 (–0.127 to –0.017)
CI = confidence interval, DTSQ = Diabetes Treatment Satisfaction Questionnaire, EQ-5D = EuroQol-5D, RCT = randomized controlled trial, WBQ = Well-being Questionnaireblood glucose levels in patients with type 2 diabetes 
managed without insulin across a wide range of out-
comes,  over  numerous  clinically  relevant  subgroups 
and through a number of detailed sensitivity analyses. 
In particular, we assessed the effect of patient educa-
tion on the efficacy of self-monitoring, a factor that is 
commonly cited as being central to obtaining benefits 
from use of the technology. 
Despite  these  strengths,  certain  limitations  of  our 
analysis  warrant  mention.  We  may  have  overlooked 
potentially relevant studies by excluding non–English-
language  articles  in  the  literature  search.  However,  a 
number of reviews on methodology have suggested that 
this practice has minimal impact on the results of sys-
tematic  reviews  and  meta-analyses.59–62  Furthermore, 
previous systematic reviews in this area did not iden-
tify additional RCTs published in a language other than 
English;10–14,16 hence, the likelihood of bias arising from 
the imposed language restriction is minimal. Another 
limitation is the relatively low statistical power to detect 
differences within some subgroups; however, it is reas-
suring that the HbA1c point estimates across subgroups 
were generally similar.
Possible limitations in the internal validity and gen-
eralizability of the RCTs included in this review should 
be noted. The lack of blinding may have resulted in over-
estimation of benefits of self-monitoring, because par-
ticipants randomly assigned to self-monitoring may have 
been more motivated to perform other behaviours that 
resulted in better glycemic control. However, it could be 
argued that any effects of self-monitoring in terms of in-
creased patient motivation are important ancillary bene-
fits that may also be realized in clinical practice; hence, 
they do not necessarily limit the internal validity of stud-
ies. Perhaps more importantly, only 1 RCT45 described a 
treatment algorithm in which results of self-monitoring 
were used to adjust antidiabetes treatments. The remain-
ing studies either based therapeutic decisions on HbA1c 
levels8,24,31,35  or  did  not  specify  how  treatments  were 
modified in response to self-monitoring test results.25,34 
Furthermore, the degree to which participants acted ap-
propriately in response to test results was not documented 
in studies, even when education regarding interpretation 
and application of test results was provided. Therefore, 
the benefits of self-monitoring, particularly in combina-
tion with patient education, may have been underesti-
mated. However, results of qualitative research indicate 
that  self-monitoring  results  are  not  often  reviewed  by 
physicians;63 hence, the manner in which self-monitoring 
was used in the RCTs included in our review may not be 
entirely unreflective of clinical practice. 
The  remaining  limitations  stem  from  the  paucity 
of  studies  addressing  key  issues  pertaining  to  self- 
monitoring in patients with type 2 diabetes who do not 
use insulin. Much of the evidence of the efficacy of self-
monitoring of blood glucose levels relates to HbA1c lev-
els  rather  than  prevention  of  complications  related  to 
diabetes. Whether HbA1c concentration is an adequate 
surrogate outcome for clinically relevant outcomes in pa-
tients with type 2 diabetes is controversial, especially in 
terms of the risk for cardiovascular events.64,65 There was 
also insufficient evidence regarding optimal frequency 
or timing of self-monitoring. Although some studies im-
plemented patient education about how to interpret test 
results, there was considerable heterogeneity in both the 
format and intensity of education and cointerventions 
provided.  Therefore,  specific  educational  components 
that  are  of  value  in  conjunction  with  self-monitoring 
could not be identified. Finally, patients with type 2 dia-
betes managed without insulin represent a heterogen-
eous clinical population. Therefore, certain subgroups 
(e.g., patients undergoing significant changes in medica-
tion regimen) may be more likely than others to bene-
fit from self-monitoring. Further studies are needed to 
adequately define the place of self-monitoring in these 
subgroups.
Conclusion.  Our  findings  suggest  that  self-monitor-
ing  of  blood  glucose  levels  is  associated  with  modest 
improvements in glycemic control among patients with 
type 2 diabetes managed without insulin. The provision 
of education to help patients translate results from self-
monitoring into appropriate responses appeared to re-
sult in no greater benefit than self-monitoring without 
education, although studies may have been limited in 
their ability to adequately assess the effects of education. 
The limited evidence regarding health-related quality of 
life and patient satisfaction indicated no benefit of self-
monitoring on these outcomes. There was insufficient 
evidence to determine the effect of self-monitoring on 
long-term complications and mortality, or to define an 
optimal testing frequency. Additional high-quality RCTs 
of sufficient size and duration are required to determine 
whether self-monitoring reduces the burden of diabetes 
complications, and to identify the patient subgroups and 
clinical scenarios in which self-monitoring is most likely 
to provide benefit.
Contributors: All of the authors contributed to the conception and 
design of the study. Brendan McIntosh, Changhua Yu, Avtar Lal, Kris-
ten Chelak and Chris Cameron extracted data from the primary stud-
ies and analyzed and interpreted the results. Sumeet Singh provided 
Open Medicine 2010;4(2):e110
Review                                                                                                                                    McIntosh et al.oversight for the extraction, analysis and interpretation of the data. 
Brendan McIntosh wrote the first draft of the manuscript. Chris Cam-
eron, Sumeet Singh and Marshall Dahl assisted in drafting the manu-
script. All of the authors critically reviewed the manuscript and ap-
proved the final version submitted for publication.  Sumeet Singh is 
the corresponding author and guarantor for the research.
Acknowledgments: We thank Dr. Heather Bennett for assisting in the 
initial stages of this project, Melissa Severn for developing and imple-
menting the literature search strategies, Zemin Bai for verifying the 
accuracy of results, Wendy Prichett-Pejic and Samantha Verbrugghe 
for assistance with data management, and Dr. Scott Klarenbach and 
Denis Bélanger for critical review.  
This systematic review was conducted by researchers at the Canadian 
Agency for Drugs and Technologies in Health (CADTH). CADTH is an in-
dependent, not-for-profit agency funded by Canadian federal, provin-
cial and territorial governments to provide credible, impartial advice 
and evidence-based information about the effectiveness of drugs and 
other health technologies to Canadian health care decision-makers 
For more information, visit www.cadth.ca.
References
1.   UK Prospective Diabetes Study Group. Tight blood pressure con-
trol and risk of macrovascular and microvascular complications 
in  type  2  diabetes:  UKPDS  38.  BMJ  1998;317(7160):703–713. 
Available:  http://www.bmj.com/cgi/reprint/317/7160/703  (ac-
cessed 2010 Apr 8). 
2.  Canadian Diabetes Association 2008 clinical practice guidelines 
for the prevention and management of diabetes in Canada. Can J 
Diabetes 2008;32(Suppl 1):S1–S201. Available: http://www.dia-
betes.ca/files/cpg2008/cpg-2008.pdf (accessed 2010 Apr 8). 
3.   Report from the National Diabetes Surveillance System: dia-
betes in Canada, 2008. Ottawa: Public Health Agency of Canada; 
2008.  Available:  http://www.phac-aspc.gc.ca/publicat/2008/
ndssdic-snsddac-08/index-eng.php (accessed 2010 Apr 8). 
4.   The prevalence and costs of diabetes. Toronto: Canadian Dia-
betes  Association;  2007.  Available:  http://www.diabetes.ca/
Files/prevalence-and-costs.pdf (accessed 2010 Apr 8). 
5.  Schütt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, et 
al. Is the frequency of self-monitoring of blood glucose related 
to long-term metabolic control? Multicenter analysis including 
24,500 patients from 191 centers in Germany and Austria. Exp 
Clin Endocrinol Diabetes 2006;114(7):384–388.
6.  Coster  S,  Gulliford  MC,  Seed  PT,  Powrie  JK,  Swaminathan  R. 
Monitoring blood glucose control in diabetes mellitus: a systematic 
review. Health Technol Assess 2000;4(12). Available: http://www.
hta.nhs.uk/execsumm/summ412.shtml (accessed 2010 Apr 8).
7.  Davidson MB. Counterpoint: self-monitoring of blood glucose in 
type 2 diabetic patients not receiving insulin. A waste of money. 
Diabetes  Care  2005;28(6):1531–1533.  Available:  http://care.
diabetesjournals.org/cgi/content/full/28/6/1531 (accessed 2010 
Apr 8).
8.  Davidson MB, Castellanos M, Kain D, Duran P. The effect of self 
monitoring of blood glucose concentrations on glycated hemoglo-
bin levels in diabetic patients not taking insulin: a blinded, ran-
domized trial. Am J Med 2005;118(4):422–425.
9.  Canadian Optimal Medication Prescribing and Utilization Ser-
vice (COMPUS), for the Canadian Agency for Drugs and Technol-
ogies in Health. Current utilization of blood glucose test strips 
in Canada. Ottawa: The Agency; 2009. Available: http://www.
cadth.ca/media/pdf/compus_CU_Report-BGTS.pdf  (accessed 
2010 Apr 8). 
10.  Towfigh A, Romanova M, Weinreb JE, Munjas B, Suttorp MJ, 
Zhou A, et al. Self-monitoring of blood glucose levels in patients 
with type 2 diabetes mellitus not taking insulin: a meta-analysis. 
Am J Manag Care 2008;14(7):468–475.
11.  Sarol JN, Nicodemus NA, Tan KM, Grava MB. Self-monitoring 
of blood glucose as part of a multi-component therapy among 
non-insulin requiring type 2 diabetes patients: a meta-analysis 
(1966–2004). Curr Med Res Opin 2005;21(2):173–183.
12.  Poolsup N, Suksomboon N, Jiamsathit W. Systematic review of the 
benefits of self-monitoring of blood glucose on glycemic control in 
type 2 diabetes patients. Diabetes Technol Ther 2008;10(Suppl 
1):S51–S66. 
13.  Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: 
a  Bayesian  meta-analysis  of  direct  and  indirect  comparisons. 
Curr Med Res Opin 2006;22(4):671–681.
14. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, 
Stalman WA, et al. Self-monitoring of blood glucose in patients 
with type 2 diabetes who are not using insulin: a systematic re-
view. Diabetes Care 2005;28(6):1510–1517. Available: http://care.
diabetesjournals.org/cgi/content/full/28/6/1510  (accessed  2010 
Apr 8).
15.  McGeoch G, Derry S, Moore RA. Self-monitoring of blood glucose 
in type-2 diabetes: What is the evidence? Diabetes Metab Res Rev 
2007;23(6):423–440.
16.  St John A, Davis WA, Price CP, Davis TME. The value of self-mon-
itoring of blood glucose: a review of recent evidence. J Diabetes 
Complicat 2010;24(2):129–141.
17.  Canadian Optimal Medication Prescribing and Utilization Service 
(COMPUS), for the Canadian Agency for Drugs and Technologies 
in Health. Use of blood glucose test strips for the management of 
diabetes mellitus – project protocol. Ottawa: The Agency; 2008. 
Available:  http://www.cadth.ca/media/compus/reports/BGTS_
Summary_Protocol_FINAL.pdf (accessed 2010 Apr 8). 
18.  Canadian Optimal Medication Prescribing and Utilization Service 
(COMPUS); the Canadian Agency for Drugs and Technologies in 
Health. Systematic review of use of blood glucose test strips for 
the management of diabetes mellitus. Ottawa: The Agency; 2008. 
Available:  http://www.cadth.ca/media/pdf/BGTS_SR_Report_
of_Clinical_Outcomes.pdf (accessed 2010 Apr 8). 
19.  Schulz  KF,  Chalmers  I,  Hayes  RJ,  Altman  DG.  Empirical  evi-
dence of bias. Dimensions of methodological quality associated 
with estimates of treatment effects in controlled trials. JAMA 
1995;273(5):408–412.
20. Higgins J, Green S, editors. Cochrane handbook for systematic 
reviews  of  interventions  [Internet].  Version  4.2.6.  Chichester 
(UK): John Wiley & Sons; 2006. Available: http://www.cochrane.
org/training/cochrane-handbook (accessed 2010 Apr 8). 
21.  DerSimonian R, Laird N. Meta-analysis in clinical trials. Control 
Clin Trials 1986;7(3):177–188.
22.  Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring 
inconsistency in meta-analyses. BMJ 2003;327(7414):557–560.  
23. French DP, Wade AN, Yudkin P, Neil AW, Kinmonth AL, Farmer 
AJ. Self-monitoring of blood glucose changed non-insulin treated 
type 2 diabetes patients’ beliefs about diabetes and self-moni-
toirng in a randomised trial. Diabet Med 2008;25(10):1218–1228.
24. Guerci B, Drouin P, Grangé V, Bougnères P, Fontaine P, Kerlan 
V, et al. Self-monitoring of blood glucose significantly improves 
metabolic control in patients with type 2 diabetes mellitus: the 
Auto-Surveillance  Intervention  Active  (ASIA)  study.  Diabetes 
Metab 2003;29(6):587–594.
25. Schwedes U, Siebolds M, Mertes G; SMBG Study Group. Meal-
related  structured  self-monitoring  of  blood  glucose:  effect  on 
diabetes control in non–insulin-treated type 2 diabetic patients. 
Diabetes Care 2002;25(11):1928–1932. Available: http://care.dia-
betesjournals.org/cgi/reprint/25/11/1928 (accessed 2010 Apr 8).
26. Meier JL, Swislocki AL, Lopez JR, Noth RH, Bartlebaugh P, Siegel 
D. Reduction in self-monitoring of blood glucose in persons with 
type 2 diabetes results in cost savings and no change in glycemic 
control. Am J Manag Care 2002;8(6):557–565.
Open Medicine 2010;4(2):e111
Review                                                                                                                                    McIntosh et al.27.  Karter AJ, Ackerson LM, Darbinian JA, D’Agostino RB, Ferrara 
A, Liu J, et al. Self-monitoring of blood glucose levels and gly-
cemic control: the Northern California Kaiser Permanente Dia-
betes Registry. Am J Med 2001;111(1):1–9.
28. Murata GH, Duckworth WC, Shah JH, Wendel CS, Mohler MJ, 
Hoffman RM. Blood glucose monitoring is associated with bet-
ter glycemic control in type 2 diabetes: a database study. J Gen 
Intern Med 2009;24(1):48–52.
29. Bonomo K, De Salve A, Pignatelli S, Fiora E, Mularoni E, Cavalot 
F, et al. Self-monitoring of blood glucose in type 2 diabetic pa-
tients not on insulin treatment: Waist of money or tool to reach 
the  glyeaemic  targets?  [abstract].  Diabetologia  2006;49(Suppl 
1):495, SEP. 
30. Davis WA, Bruce DG, Davis TME. Does self-monitoring of blood 
glucose improve outcome in type 2 diabetes? The Fremantle Dia-
betes Study. Diabetologia 2007;50(3):510–515.
31.  Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. 
Impact of self monitoring of blood glucose in the management of 
patients with non-insulin treated diabetes: open parallel group 
randomised trial. BMJ 2007;335(7611):132.
32. Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, 
et al. Longitudinal study of new and prevalent use of self-monitor-
ing of blood glucose. Diabetes Care 2006;29(8):1757–1763. Avail-
able: http://care.diabetesjournals.org/cgi/reprint/29/8/1757 (ac-
cessed 2010 Apr 8).
33. Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, Kolb 
H, et al. Self-monitoring of blood glucose in type 2 diabetes and 
long-term outcome: an epidemiological cohort study. Diabetolo-
gia 2006;49(2):271–278.
34. Muchmore  DB,  Springer  J,  Miller  M.  Self-monitoring  of  blood 
glucose  in  overweight  type  2  diabetic  patients.  Acta  Diabetol 
1994;31(4):215–219.
35. O’Kane MJ, Bunting B, Copeland M, Coates VE: ESMON study 
group. Efficacy of self monitoring of blood glucose in patients 
with newly diagnosed type 2 diabetes (ESMON study): random-
ised controlled trial. BMJ 2008;336(7654):1174–1177.
36. Rindone JP, Austin M, Luchesi J. Effect of home blood glucose 
monitoring  on  the  management  of  patients  with  non-insulin 
dependent diabetes mellitus in the primary care setting. Am J 
Manag Care 1997;3(9):1335–1338.
37.  Secnik K, Yurgin N, Lage MJ. Patterns of blood glucose monitor-
ing in relation to glycemic control among patients with type 2 dia-
betes in the UK. J Diabetes Complicat 2007;21(3):181–186.
38. Siebolds M, Gaedeke O, Schwedes U; SMBG Study Group. Self-
monitoring of blood glucose—psychological aspects relevant to 
changes in HbA1c in type 2 diabetic patients treated with diet 
or  diet  plus  oral  antidiabetic  medication.  Patient  Educ  Couns 
2006;62(1):104–110.
39. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A; Diabetes 
Glycemic Education and Monitoring Trial Group. Cost effective-
ness of self monitoring of blood glucose in patients with non-insu-
lin treated type 2 diabetes: economic evaluation of data from the 
DiGEM trial. BMJ 2008;336(7654):1177–1180. Available: http://
www.bmj.com/cgi/reprint/336/7654/1177 (accessed 2010 Apr 8).
40. Soumerai SB, Mah C, Zhang F, Adams A, Barton M, Fajtova V, 
et  al.  Effects  of  health  maintenance  organization  coverage  of 
self-monitoring devices on diabetes self-care and glycemic con-
trol.  Arch  Intern  Med  2004;164(6):645–652.  Available:  http://
archinte.ama-assn.org/cgi/reprint/164/6/645  (accessed  2010 
Apr 8).
41.  Wen  L,  Parchman  ML,  Linn  WD,  Lee  S.  Association  between 
self-monitoring  of  blood  glucose  and  glycemic  control  in  pa-
tients with type 2 diabetes mellitus. Am J Health Syst Pharm 
2004;61(22):2401–2405.
42. Wieland LD, Vigil JM, Hoffman RM, Janis LW. Relationship be-
tween home glucose testing and hemoglobin A1c in type II dia-
betes patients. Am J Health Syst Pharm 1997;54(9):1062–1065.
43. Scherbaum WA, Ohmann C, Abholz HH, Dragano N, Lankisch 
M. Effect of the frequency of self-monitoring blood glucose in 
patients  with  type  2  diabetes  treated  with  oral  antidiabetic 
drugs—a multi-centre, randomized controlled trial. PLoS ONE 
2008;3(8):e3087.
44. Bajkowska-Fiedziukiewicz A, Cypryk K, Kozdrap T, Mikołajczyk-
Swatko A, Józefowska M, Kosiński M, Józefowska M. Self-mon-
itoring of blood glucose and treatment outcomes in type 2 dia-
betic patients. Pol Arch Med Wewn 2008;118(5):267–272.
45. Barnett AH, Krentz AJ, Strojek K, Sieradzki J, Azizi F, Embong M, 
et al. The efficacy of self-monitoring of blood glucose in the man-
agement of patients with type 2 diabetes treated with a gliclazide 
modified  release-based  regimen.  A  multicentre,  randomized, 
parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes 
Obesity Metab 2008;10(12):1239–1247.
46. Farmer A, Wade A, French D, Simon J, Yudkin P, Gray A, et al. 
Blood glucose self-monitoring in type 2 diabetes: a randomised 
controlled trial. Health Technol Assess 2009;13(15):1–72.
47.  Schneider B, Martin S, Heinemann L, Lodwig V, Kolb H. Inter-
relations between diabetes therapy, self-monitoring of blood glu-
cose, blood glucose and non-fatal or fatal endpoints in patients 
with type 2 diabetes: results of a longitudinal cohort study (ROS-
SO 5). Arzneimittelforschung 2007;57(12):762–769.
48. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis 
detected by a simple, graphical test. BMJ 1997;315(7109):629–
634.
49. Bowker  SL,  Majumdar  SR,  Johnson  JA.  Systematic  review 
of  indicators  and  measurements  used  in  controlled  stud-
ies of quality improvement for type 2 diabetes. Can J Diabetes 
2005;29(3):230–238.  Available:  http://www.diabetes.ca/files/
Johnson_Systematic_Review-pages%20230-238.pdf  (accessed 
2010 Apr 8).
50. Majumdar SR, Johnson JA, Bowker SL, Booth GL, Dolovich L, 
Ghali W, et al. A Canadian consensus for the standardized evalua-
tion of quality improvement interventions in type 2 diabetes. Can 
J Diabetes 2005;29(3):220–229.
51.  McAndrew L, Schneider SH, Burns E, Leventhal H. Does patient 
blood glucose monitoring improve diabetes control? A systematic 
review of the literature. Diabetes Educ 2007;33(6):991–1011.
52. Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S. Glycemic 
control and morbidity in the Canadian primary care setting (re-
sults of the Diabetes in Canada Evaluation Study). Diabetes Res 
Clin Pract 2005;70(1):90–97.
53. Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-mon-
itoring in non-insulin-treated type 2 diabetes: a qualitative study 
of patients’ perspectives. Br J Gen Pract 2004;54(500):183–188.
54. Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in 
type 2 diabetes: longitudinal qualitative study of patients’ per-
spectives. BMJ 2007;335(7618):493. Available: http://www.bmj.
com/cgi/reprint/335/7618/493 (accessed 2010 Apr 8).
55. Carroll AE, Downs SM, Marrero DG. What adolescents with type 
I  diabetes  and  their  parents  want  from  testing  technology:  a 
qualitative study. Comput Inform Nurs 2007;25(1):23–29.
56. Shiu AT, Kwan JJY, Wong RY. Research in brief. Social stigma as a 
barrier to diabetes self-management: implications for multi-level 
interventions. J Clin Nurs 2003;12(1):149–150.
57.  Hall RF, Joseph DH, Schwartz-Barcott D. Overcoming obstacles 
to behavior change in diabetes self-management. Diabetes Educ 
2003;29(2):303–311.
Open Medicine 2010;4(2):e112
Review                                                                                                                                    McIntosh et al.58. Nyomba BL, Berard L, Murphy LJ. Facilitating access to glucom-
eter reagents increases blood glucose self-monitoring frequency 
and improves glycaemic control: a prospective study in insulin-
treated diabetic patients. Diabet Med 2004;21(2):129–135.
59. Moher D, Pham B, Klassen TP, Schulz KF, Berlin JA, Jadad AR, et 
al. What contributions do languages other than English make on 
the results of meta-analyses? J Clin Epidemiol 2000;53(9):964–
972.
60. Moher  D,  Pham  B,  Lawson  ML,  Klassen  TP.  The  inclusion  of   
reports  of  randomised  trials  published  in  languages  other 
than  English  in  systematic  reviews.  Health  Technol  Assess 
2003;7(41):1–90.  Available:  http://www.hta.ac.uk/execsumm/
summ741.shtml (accessed 2010 Apr 8).
61.  Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and 
impact of language bias in meta-analyses of controlled trials: em-
pirical study. Int J Epidemiol 2002;31(1):115–123.
62. Morrison A, Moulton K, Clark M, Polisena J, Fiander M, Mie-
rzwinski-Urban  M,  et  al.  English-language  restriction  when 
conducting  systematic  review-based  meta-analyses:  systematic 
review of published studies. Ottawa: Canadian Agency for Drugs 
and  Technologies  in  Health;  2009.  Available:  http://cadth.ca/
media/pdf/H0478_Language_Restriction_Systematic_Re-
view_Pub_Studies_e.pdf (accessed 2010 Apr 8). 
63. Canadian  Agency  for  Drugs  and  Technologies  in  Health.  Cur-
rent practice analysis of health care providers and patients on 
self-monitoring  of  blood  glucose.  Ottawa:  The  Agency;  2009. 
Available:  http://www.cadth.ca/media/pdf/compus_Current_
Practice_Report_Vol-3-Issue-5.pdf (accessed 2010 Apr 8). 
64. Ewart  RM.  The  case  against  aggressive  treatment  of  type  2 
diabetes:  critique  of  the  UK  prospective  diabetes  study.  BMJ 
2001;323(7317):854–858.
65. Rosen CJ. The rosiglitazone story—lessons from an FDA Advisory 
Committee meeting. N Engl J Med 2007;357(9):844–846.
66. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. 
Evaluation of a pharmaceutical care model on diabetes manage-
ment. Ann Pharmacother 1996;30(3):238–243.
67.  Miles P, Everett J, Murphy J, Kerr D. Comparison of blood or urine 
testing by patients with newly diagnosed non-insulin dependent 
diabetes: patient survey after randomised crossover trial. BMJ 
1997;315(7104):348–349.
68. Kibriya MG, Ali L, Banik NG, Khan AK. Home monitoring of blood 
glucose  (HMBG)  in  Type-2  diabetes  mellitus  in  a  developing 
country. Diabetes Res Clin Pract 1999;46(3):253–257.
69. Kwon HS, Cho JH, Kim HS, Song BR, Ko SH, Lee JM, et al. Estab-
lishment  of  blood  glucose  monitoring  system  using  the  Inter-
net. Diabetes Care 2004;27(2):478–483. Available: http://care.
diabetesjournals.org/cgi/reprint/27/2/478 (accessed 2010 Apr 8).
70. Moreland EC, Volkening LK, Lawlor MT, Chalmers KA, Anderson 
BJ, Laffel LM. Use of a blood glucose monitoring manual to en-
hance monitoring adherence in adults with diabetes: a random-
ized controlled trial. Arch Intern Med 2006;166(6):689–695.
71.  Rutten G, van Eijk J, de Nobel E, Beek M, van der Velden H. Feas-
ibility and effects of a diabetes type II protocol with blood glucose 
self-monitoring in general practice. Fam Pract 1990;7(4):273–
278.
72. Estey AL, Tan MH, Mann K. Follow-up intervention: its effect 
on compliance behavior to a diabetes regimen. Diabetes Educ 
1990;16(4):291–295.
73. Allen BT, DeLong ER, Feussner JR. Impact of glucose self-mon-
itoring on non-insulin-treated patients with type II diabetes mel-
litus. Randomized controlled trial comparing blood and urine 
testing. Diabetes Care 1990;13(10):1044–1050.
74. Wing RR, Epstein LH, Nowalk MP, Scott N, Koeske R, Hagg S. 
Does  self-monitoring  of  blood  glucose  levels  improve  dietary 
compliance for obese patients with type II diabetes? Am J Med 
1986;81(5):830–836.
75. Fontbonne  A,  Billault  B,  Acosta  M,  Percheron  C,  Varenne  P, 
Besse  A,  et  al.  Is  glucose  self-monitoring  beneficial  in  non-
insulin-treated  diabetic  patients?  Results  of  a  random-
ized  comparative  trial.  Diabete  Metab  1989;15(5):255–260.
 
Citation: McIntosh B, Yu C, Lal A, Chelak K, Cameron C, Singh SR, 
Dahl M. Efficacy of self-monitoring of blood glucose in patients with 
type  2  diabetes  mellitus  managed  without  insulin:  a  systematic   
review and meta-analysis. Open Med 2010;4(2):e102-13.
Published: 18 May 2010
Copyright: Open Medicine applies the Creative Commons Attribution 
Share Alike Licence, which means that anyone is able to freely copy, 
download, reprint, reuse, distribute, display or perform this work and 
that authors retain copyright of their work. Any derivative use of this 
work must be distributed only under a licence identical to this one 
and must be attributed to the authors. Any of these conditions can be 
waived with permission from the copyright holder. These conditions 
do not negate or supersede Fair Use laws in any country.
Open Medicine 2010;4(2):e113
Review                                                                                                                                    McIntosh et al.